[go: up one dir, main page]

DE69113802D1 - Anwendung von beta-alethin in zellkultur und therapie. - Google Patents

Anwendung von beta-alethin in zellkultur und therapie.

Info

Publication number
DE69113802D1
DE69113802D1 DE69113802T DE69113802T DE69113802D1 DE 69113802 D1 DE69113802 D1 DE 69113802D1 DE 69113802 T DE69113802 T DE 69113802T DE 69113802 T DE69113802 T DE 69113802T DE 69113802 D1 DE69113802 D1 DE 69113802D1
Authority
DE
Germany
Prior art keywords
therapy
application
cell culture
alethine
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69113802T
Other languages
English (en)
Other versions
DE69113802T2 (de
Inventor
Galen Knight
Paul Mann
Terence Scallen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of New Mexico UNM
Original Assignee
University of New Mexico UNM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of New Mexico UNM filed Critical University of New Mexico UNM
Publication of DE69113802D1 publication Critical patent/DE69113802D1/de
Application granted granted Critical
Publication of DE69113802T2 publication Critical patent/DE69113802T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69113802T 1990-07-06 1991-07-08 Anwendung von beta-alethin in zellkultur und therapie. Expired - Fee Related DE69113802T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54910390A 1990-07-06 1990-07-06
US54910490A 1990-07-06 1990-07-06
PCT/US1991/004725 WO1992000960A1 (en) 1990-07-06 1991-07-08 Beta-alethine use in cell culture and therapy

Publications (2)

Publication Number Publication Date
DE69113802D1 true DE69113802D1 (de) 1995-11-16
DE69113802T2 DE69113802T2 (de) 1996-05-15

Family

ID=27069009

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69113802T Expired - Fee Related DE69113802T2 (de) 1990-07-06 1991-07-08 Anwendung von beta-alethin in zellkultur und therapie.

Country Status (9)

Country Link
EP (1) EP0538330B1 (de)
JP (1) JP3319597B2 (de)
AT (1) ATE128964T1 (de)
AU (1) AU646875B2 (de)
DE (1) DE69113802T2 (de)
DK (1) DK0538330T3 (de)
ES (1) ES2080954T3 (de)
GR (1) GR3018632T3 (de)
WO (1) WO1992000960A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3259960B2 (ja) * 1990-07-06 2002-02-25 ユニバシテイ オブ ニュー メキシコ 細胞培養及び治療に有用なビタレテイン
US6245561B1 (en) 1990-07-06 2001-06-12 University Of New Mexico β-alethine use in cell culture and therapy
US5643966A (en) * 1990-07-06 1997-07-01 University Of New Mexico β-alethine as anti-tumor agent
AU4372393A (en) * 1993-05-12 1994-12-12 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
WO1997014306A1 (en) * 1995-10-17 1997-04-24 Dovetail Technologies, Inc. Low molecular weight cell, bone marrow and immune stimulants
US6762174B1 (en) 1998-02-24 2004-07-13 Dovetail Technologies, Inc. Low molecular weight compounds administered together with anti-cancer agents to prevent or treat cancer and pharmaceutical compositions thereof
US6414114B2 (en) * 1998-02-24 2002-07-02 Dovetail Technologies, Inc. Disulfides and thiol compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552765A (en) * 1982-05-14 1985-11-12 Santen Pharmaceutical Co., Ltd. Aletheine derivatives

Also Published As

Publication number Publication date
GR3018632T3 (en) 1996-04-30
JP3319597B2 (ja) 2002-09-03
AU646875B2 (en) 1994-03-10
DK0538330T3 (da) 1996-02-26
EP0538330A4 (en) 1993-07-07
DE69113802T2 (de) 1996-05-15
EP0538330B1 (de) 1995-10-11
EP0538330A1 (de) 1993-04-28
WO1992000960A1 (en) 1992-01-23
AU8207791A (en) 1992-02-04
ATE128964T1 (de) 1995-10-15
ES2080954T3 (es) 1996-02-16
JPH05508769A (ja) 1993-12-09

Similar Documents

Publication Publication Date Title
DE3860043D1 (de) Verwendung von biertreberextrakt zur herstellung von medizinischen und kosmetischen zubereitungen.
BR9910251A (pt) Estimulação hematopoiética
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
DE59108854D1 (de) Arzneimittel sowie deren herstellung und deren verwendung bei der bekämpfung von schmerzen und/oder entzündungen an tieren und menschen
AU6649996A (en) Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
ATE111735T1 (de) Verwendung des wirkstoffs azelastin und glycerinethern zur bekämpfung von psoriasis- erkrankungen.
ATE81776T1 (de) Verwendung von chinolon und naphthyridinantibiotika zur herstellung von ophthalmischen arzneimitteln.
ATE311191T1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
ATE172117T1 (de) Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
DE69113802D1 (de) Anwendung von beta-alethin in zellkultur und therapie.
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
ES2107414T3 (es) Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis.
NO931413L (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
Winickoff et al. Urine culture after treatment of uncomplicated cystitis in women
NO162557C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive (pyrrol-1-yl)-fenyldihydropyridazinoner.
SE8102161L (sv) "3,7,11,15-tetrametyl-2,4,6,10,14-hexadekapentaensyra
HUT63441A (en) Megakariocyte colony stimultating factor protein
ES2149347T3 (es) Composiciones farmaceuticas de verotoxinas y tratamientos medicos con las mismas.
PT1016414E (pt) Hormona de crescimento humano para estimular a hematopoiese e a reconstituicao imnologica apos transplante de celulas estaminais hematopoieticas em humanos
ZA885625B (en) Therapeutic agents containing enantiomers of propafenone
ATE186048T1 (de) Vitalethin und seine anwendung in zellkultur und therapie
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
Pashchenko et al. Effect of alcoholic patients' serum on the reproductive activity of human embryo fibroblasts
BG49742A1 (en) Affrodisiance means

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: HANSMANN & VOGESER, 81369 MUENCHEN

8339 Ceased/non-payment of the annual fee